INTRODUCTION
The 68 Ge/ 68 Ga radionuclide generator, with its secular equilibrium mathematics, offers a perfect combination of the nuclidic parameters in terms of half-lives and emission profiles: t½ = 270.95 days for 68 Ge and t½ = 67.71 minutes for 68 Ga, with no photon emission for 68 Ge and an 89.14% positron branching for 68 Ga. 10, 46 This was known already in the middle of the 20th century, yet gallium-68 today sees a renaissance, with the development of new 68 Ge/ 68 Ga radionuclide generators, sophisticated 68 Ga radiopharmaceuticals, and state-of-the-art clincial diagnoses via positron emission tomography/computed tomography (PET/CT). 43 Current advances represent a 'renaissance' because 68 Ga is one of the very early radionuclides applied to PET imaging. Its application preceeds the use of fluorine-18 and even the term 'positron emission tomorgaphy'. Moreover, the availability of this positron emitter via the first 68 Ge/ 68 Ga generators, 16, 17 lead to the development of the first positron scintillation camera which was created in the beginning of the 1960s. With the availability of the first 68 Ge/ 68 Ga generators (which provided 68 Ga-EDTA eluates) and dramatically
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improved tomographic detection systems, several 68 Ga tracers for imaging of various diseases were investigated (mainly for imaging the human brain). Hundreds of patients were investigated in the USA using 68 Ga-EDTA, and others from 1963 on.
Despite several publications describing 'improved' 68 Ge/ 68 Ga radionuclide generators, the impact of 68 Ga imaging subsided in the late 1970s. This was primarily a consquence of two genertaor-related factors. Firstly, the generator design was inadequate for the versatile synthesis of 68 Ga radiopharmaceuticals. Secondly, in view of the parallel and rapid developments of the new classes of 99m
Tc-and 18 F-labeled diagnostics, the 68 Ge/ 68 Ga generators had only minor clinical relevance. Nevertheless, numerous papers in the 1970s and 1980s described the use of inorganic matrixes and organic resins, which allow for the isolation of 68 Ga from 68 Ge within hydrochloric acid solutions of weak (0.1-1.0 N) or strong (>1 N) concentrations respectively.
Pioneering achievement of radiochemists in Obninsk, Russia, resulted in the development of a new type of 68 Ge/ 68 Ga generator which became commercially available in the first years of the 21st century. 40 Generator eluates based on hydrochloric acid provided 'cationic' 68 Ga instead of 'inert' 68 Ga-complexes, opening new pathways of Me III based radiopharmaceutical chemistry. Initially, the 68 Ga cation was introduced into existing ligands used for magnetic resonance imaging (MRI) and SPECT imaging probes, such as DTPAor DOTA-based derivatives. The impressive results achieved using 68 Ga-DOTA-octreotides for PET/CT compared to 111 In-DTPA-octroescan paved the way toward the clinical acceptance of this particular tracer for imaging neuroendocrine tracers, and highlighted the great potential of the 68 Ge/ 68 Ga generator for modern nuclear medicine in general. These advances intiated a 68 Ga rush in recent times (post 2002). However, the widespread acceptance and clinical application of 68 Ga radiopharmaceuticals requires optimization of 68 Ge/ 68 Ga generators both from chemical and regulatory points of view. Furthermore, dedicated chelators are required to broaden the possibilities of 68 Ga labeling to allow the use of more sensitive targeting vectors. Last but not least, this should also involve applying the concept of 68 Ga-radiopharmaceutical chemistry to an increasing number of targeting vectors, addressing the clinically most relevant diseases. Ga radionuclide, it is possible that in another decade from now 68 Ge/ 68 Ga generator-based 68 Ga diagnostics may approach a top three ranking in imaging (together with 99m Tc-and 18 F-based tracer diagnostics).
This paper includes material which was presented at the 1st World Congress on Ga-68 and peptide receptor radionuclide therapy (PRRNT) theranostics-on the way to personalized medicine, Bad Berka, Germany, Junge 23-26, 2011, and which were published at a later stage.
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THE EARLY YEARS (1960-1970):
THE SUNRISE OF 68 
Ga
The First 68 Ge/ 68 
Ga Radionuclide Generators
The first 68 Ge/ 68 Ga radionuclide generator was described in 1960 16 and entitled: 'A positron cow'. As the title elicits, the concept was to use a radionuclide generator for the production of a positron emitting radionuclide. The latter was a new entry for radiopharmaceutical chemistry and nuclear medicine molecular imaging in vivo. The generator chemistry involved a liquid-liquid extraction, and the whole processing protocol was considerably different to that of current radionuclide generator systems. Nevertheless, a variety of 68 Ga compounds were synthesized using this generator design.
2,7,44
Further Generator Developments: Al 2 O 3 -based
EDTA-Eluted Generators
Inherent disadvantages of the first generator lead to the development of two improved generator concepts soon after. The liquid-liquid extraction chemistry introduced by Gleason was substituted for a solid phase-based ion exchange system 17, 50 (Fig. 1) . In addition, a generator featuring an improved liquid-liquid extraction was described later. 15 The original sketch, taken from the original publication by Yano and Anger (1964) for the second solid-phase based generator is reproduced in Figure 2 . These solid-phase chromatographic generators offered excellent radiochemical characteristics. Using an alumina column and EDTA as eluent (10 ml 0.005 M EDTA), 68 Ga was easily eluted in a reproducible 95% yield without the need to introduce stable Ga III as carrier. The eluate contained as little as 1.4 × 10 -5 % of the parent 68 Ge. Prior to in vivo injection, 0.5 ml of 18% NaCl solution was added to the eluate.
Ge/ Ga Generators and the Development of Positron Scintillation Cameras
This system served as a convenient and economical source of 68 Ga-EDTA. Effectively, this radionuclide generator was a synthesis unit of a relevant radiopharmaceutical; 68 Ga-EDTA (named 'veronate' at the time). 68 Ga-EDTA, and limited other 68 Ga-tracers, were adapted for human application quite quickly by various groups in the United States for early applications. 20, 21, 44 Systematic application for brain imaging was reported, with medical impact having significant dependence on the method of detection applied. Conventional imaging appeared to be relatively difficult, with relatively high dosage of 68 Ga-EDTA required for valuable medical information to be gained. Anger thus, started to develop the basics of positron imaging tomography 2, 22, 23 (arguing as follows (Gottschalk and Anger 1964): … 'We seriously question whether satisfactory results can be obtained with the conventional positron scanner. Recent phantom studies indicate that the positron scintillation camera using 68 Ga-EDTA will detect lesions 1/2 the volume that can be detected by the conventional positron scanner using As74. The increase in sensitivity is obtained even though the phantom was set up to simulate our clinical condition where brain pictures are 68 Ge/ 68 Ga radionuclide generators II: From liquid-liquid extraction to solid phase-based elution 68 Ga elution (using an EDTA solution) reproduced from the original publication by Yano and Anger (1964) JAYPEE Frank Rösch obtained in 4 to 10 minutes with a dose of 350 to 750 microcuries of 68 Ga-EDTA. Shealy et al, however, found that 2 to 3 millicuries of 68 Ga-EDTA was sometimes an inadequate dose with their positron scanner.' Images recorded with this new type of camera ( Fig. 3) 2 paved the way for routine PET imaging.
Ga-EDTA: The Prototype PET-Pharmaceutical
Despite these new imaging features and the great success of 68 Ga-EDTA molecular imaging, the fact that in practice the generator was limited to 68 Ga-EDTA was a severe limitation. The extraction of 68 Ga from the thermodynamically very stable (log K = 21.7) 68 Ga-EDTA eluate species was not straightforward. Yano and Anger 1964 reported that, 'attempts are being made. .. to free 68 Ga ... from the EDTA complex'. A procedure was developed however; it was not user friendly and practical for 68 Ga. On a scale which uses 10 mg Ga carrier, the time required for extraction is 30 minutes, and the transfer yield of 60%. 50 The protocol was: 1. The cow is milked with 10 ml of 0.005 M EDTA solution, and the 68 Ga is collected in a 40 ml centrifuge tube.
2. The 10 to 20 mg of carrier GaCl 3 in HCl solution is added. 3. The 0.5 ml of saturated ammonium acetate solution is added. 4. Concentrated NH 4 OH is added dropwise (about 1 ml) to precipitate Ga(OH) 3 at pH 6.0. 5. The solution is heated in a boiling water bath for 10 minutes to coagulate the Ga(OH) 3 . 6. The solution is centrifuged, and the supernatant solution is discarded. 7. The Ga(OH) 3 is dissolved with a minimum volume of hot 20% NaOH. 8. The solution is acidified with about 1 ml of concentrated HCl.
HIBERNATING 68 Ga MEDICAL APPLICATIONS, BUT NEW CHEMISTRY AHEAD
The impact of 68 Ga imaging started to subside in the late 1970s, for two main reasons. Firstly, the generator design was inadequate in terms of the requirements for versatile synthesis of 68 Ga radiopharmaceuticals. Secondly, in view of the parallel and rapid developments of the new classes of 99m Tc-and 18 F-labeled diagnostics, the generators available through the existing technology had only minor clinical relevance. Despite this apparent decrease in interest, numerous basic radiochemical papers in the 1970s and 1980s described the use of inorganic matrixes as well as organic resins, selectively adsorbing 68 Ge and providing 68 Ga desorbtions within hydrochloric acid solutions of weak (0.1-1.0 N) or strong (>1 N) concentrations respectively. Cationic 68 Ga eluates are required to facilitate the versatile radiolabeling chemistry with 68 Ga. Thus, the primary challenge is the development of separation systems which provide cationic 68 Ga species. Figure 4 gives a schematic overview.
COMMERCIAL 'IONIC' GENERATORS Generator Eluates Delivering the Gallium Cation
Thanks to the pioneering achievement of radiochemists in Obninsk (Russian Federation), a new type of 68 Ge/Ga Ga-DOTA-octreotides and PET/CT instead of, e.g. 111 In-DTPA-octroescan paved the way for clinical acceptance of this particular tracer for imaging neuroendocrine tumors, but also to the realization of the great potential of the 68 Ge/ 68 Ga generator for modern nuclear medicine in general. While commercial 'ionic' generators had successfully entered clinical environments, there were questions regarding its suitability, which became more relevant. In particular these related to its adequacy concerning radiation safety, legal requirements and labeling of medical tracers became more and more relevant. The most relevant concerns are outlined:
• Problem 1: The long physical half-life of the parent in principle should give a generator shelf-life of at least 1 year. However, the shelf-life of the generators did not necessarily parallel this long physical half-life due in particular to increasing breakthrough of 68 Ge, but also decreasing 68 Ga elution yield. 68 Ge breakthrough reduction and/or removal of 68 Ge from the eluates therefore remain an important radiochemical challenge.
• Problem 2: 68 Ga generator eluates are not chemically or radiochemically pure. Nonradioactive metals, such as 68 Zn II (as generated on the generator as decay product of 68 Ga), Fe III as general chemical impurity, and 68 Ge IV as breakthrough represent metals, which may compete with 68 Ga III for coordinative labeling of radiopharmaceutical precursors. Again, this illustrates the importance of minimizing the 68 Ge content in the eluate. 4, 51 • Problem 3: The new generation of 68 Ge/ 68 Ga radionuclide generators utilize hydrochloric acid solutions for 68 Ga elution. The relatively acidic environment created many protonated functional groups of ligands and bifunctional ligands needed for the labeling of 68 Ga, which may hinder efficient radiolabeling. Finally, minimizing the pH and volume of 68 Ga eluted prior to labeling should facilitate higher radiolabeling yields.
Generator Post-Processing
Three approaches have been developed to address one or more of these problems. Two processes include chemical separation strategies, which may be referred to as 'postprocessing'. 35, 51 The third technology involves a simple fractionation of the eluate, i.e. isolating eluate fractions with highest 68 Ga concentration. 11 The methods are schematically illustrated in Figure 6 . In most cases, commercial generators are used in direct connection with one of the three postelution processing technologies mentioned. The cation exchange-based postprocessing 4,51 guarantees almost complete removal of the metallic impurities, in particular 68 Ge. Numerous modifications have been reported, including NaCl solutions instead of the solution no. 2 to desorb 68 Ga from the resin, 36 or by incorporating a subsequent anion exchange-based purification step 32 to remove organic solvent prior to labeling.
CURRENT STATE/OUTLOOK
Today, 68 Ge/ 68 Ga radionuclide generators are commercially available as TiO 2 -, SnO 2 -or organic resin-based columns. 68 Ga eluate yields range from about 70 to 80% for fresh generators, with a decrease overtime. 68 Ge breakthrough levels vary between 0.01 and 0.001% (or even less) for fresh generators, with these percentages increasing over extended periods of generator usage. Conjugated with post-processing technologies, 68 Ga radiopharmaceuticals are being synthesized routinely and safely. Thus, since the early 68 Ge/ 68 Ga radionuclide generator systems developed about half a century ago, significant advances have been made. These generator improvements have allowed for the significant development of 68 Ga radiopharmaceutical chemistry within the last decade. Despite this, almost all the technological and chemical innovation involved belongs to the 20th century. There is room for further development, where several aspects of generator design and performance, labeling chemistry and clinical application need to be addressed. Figure 7 illustrates some of the potential future directions.
Generators
Concerning solid phase-based ion exchange chromatographic 68 Ge/ 68 Ga radionuclide generators, some improvements may be possible within the resin material itself. Recent publications hint at the potential of sophisticated nanoparticles, such as Zr IV and Ce IV -systems, which are classified as nanocomposites. 12, 13 The rational is that these composites may provide effective adsorption of 68 Ge, effective release of 68 Ga, be more chemically stability and radiation resistant. In parallel, GMP-certified and licensed commercial generators are required to satisfy the increasing standards of legal authorities.
Generator Online Post-Processing
Elution of generators may be further integrated into faster and more efficient online post-processing procedures, which are managed by automated modules. A key issue in this regard, is to avoid the transfer of 68 Ge into 68 Ga-radiopharmaceuticals. Optionally, these post-processing technologies should also allow for versatile labeling protocols. For example, the transfer from aqueous to nonaqueous solutions for radiolabeling (addressing potential lipophilic 68 Ga tracers) 53 or onto resin for solid phase supported labeling reactions. Post-processing technologies, which remove 68 Ge online from the eluate, are of utmost importance, as they avoid the transfer of critical 68 Ge levels into the radiopharmaceutical preparation. They also guarantee the safety, which is relevant from the legal point of view, i.e. addressing safety criteria of routine clinical use. 9 Although some of the 68 Ga radiopharmaceuticals used clinically, in particular 68 Gabased peptides, are purified from uncomplexed 68 Ga, (which simultaneously removes 68 Ge present), the principal strategy should be to keep generator-derived 68 Ga solutions free of 68 Ge before labeling. Consequently, the monographs of the European Pharmacopoeia (Ph Eur) in its description of the gallium chloride ( 68 Ga) solution for radiolabeling, Monograph N°: 2464, Strasbourg, June 2012, adds, that '…the solution is intended for use in the preparation of gallium-68-labeled radiopharmaceuticals, including a procedure to reduce the level of germanium-68 below 0.001% of the total radioactivity.' This means that, necessarily, the procedure for preparation of a Ga-68 radiopharmaceutical has to include a procedure to remove germanium-68 up to a level below 0.001%. Only this strategy will be suitable for a kit-type 68 Galabeling approach to parallel the 99m Tc analog systems. This would allow for the direct synthesis and application of 68 Ga radiopharmaceuticals, such as 68 Ga chloride, 49 68 Ga 68 Ge/ 68 Ga radionuclide generators: (1) Direct generator elution through cation-exchange cartridge, (2) desorption of purified 68 Ga using HCl/acetone or HCl/ ethanol mixtures, (3) generator elution into HCl reservoir, (4) subsequently elution through anion-exchange cartridge, (5) desorption of purified 68 Ga using water, (6) identification of the eluate fraction representing at least two-third of the 68 Ga activity, and use without further purification Fig. 7 : Sketch of some future directions related to 68 68 Ga apotransferrin 27 or 68 Ga
Schiff base complexes. 18, 19 Radiotracers, such as these are otherwise not applicable due to the nonseparable content of 68 Ge.
Ligands
The future development of new 68 Ga radiopharmaceuticals may be facilitated by the development of new ligands and bifunctional derivatives for coordinating 68 New cyclic triazacyclononane-phosphinic acid chelators 38, 39 have been developed, which complex 68 Ga very effectively. In case of the triazacyclononanephosphinic acid chelators (TRAP), the idea is also to create an inert coordinating core leaving three linkable functionalities available for versatile chemistry, allowing for multimeric substitutions.
Ga Radiopharmaceuticals
Novel ligand design presents the opportunity for a wide range of new tracers. The clinical application, however, will finally depend on the classes of targeting vectors attached, beyond peptidic and nonpeptidic targeting vectors available. Imaging will hopefully address tumors, infection and inflammation, but also a variety of clinical indications and almost all organs. This would mirror the 99m Tc radiopharmaceuticals, e.g. brain, heart, etc. In the context of the similarity of generator based 99m Tc and 68 Ga pharmaceuticals, the preparation of those 68 Ga radiopharmaceuticals should also be KIT-based if they are to find clinical application and widespread acceptance. These developments will contribute to a much more intense clinical use of 68 Ge/ 68 Ga generators and the corresponding 68 Ga pharmaceuticals for molecular imaging. Again, legal considerations apply to both the generator and the pharmaceuticals. 
Theranostics
Simultaneously to the further development of 68 Ga-PECT/ CT diagnostics, it is one of the unique features of 68 Ga, that 68 Ga-PET/CT imaging may be directly linked to treatment options. For some classes of Ga III 
